|
1
|
Ushio J, Kanno A, Ikeda E, Ando K, Nagai
H, Miwata T, Kawasaki Y, Tada Y, Yokoyama K, Numao N, et al:
Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors.
Diagnostics (Basel). 11:5622021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neoptolemos JP, Palmer DH, Ghaneh P,
Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA,
Cunningham D, Wadsley J, et al: Comparison of adjuvant gemcitabine
and capecitabine with gemcitabine monotherapy in patients with
resected pancreatic cancer (ESPAC-4): A multicentre, open-label,
randomised, phase 3 trial. Lancet. 389:1011–1024. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee M, Kwon W, Kim H, Byun Y, Han Y, Kang
JS, Choi YJ and Jang JY: The role of location of tumor in the
prognosis of the pancreatic cancer. Cancers (Basel). 12:20362020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Birnbaum DJ, Bertucci F, Finetti P,
Birnbaum D and Mamessier E: Head and body/tail pancreatic
carcinomas are not the same tumors. Cancers (Basel). 11:4972019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ling Q, Xu X, Zheng SS and Kalthoff H: The
diversity between pancreatic head and body/tail cancers: Clinical
parameters and in vitro models. Hepatobiliary Pancreat Dis Int.
12:480–487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moffitt RA, Marayati R, Flate EL, Volmar
KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung
AH, et al: Virtual microdissection identifies distinct tumor- and
stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat
Genet. 47:1168–1178. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moll R, Franke WW, Schiller DL, Geiger B
and Krepler R: The catalog of human cytokeratins: Patterns of
expression in normal epithelia, tumors and cultured cells. Cell.
31:11–24. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O'Kane GM, Grünwald BT, Jang GH, Masoomian
M, Picardo S, Grant RC, Denroche RE, Zhang A, Wang Y, Miller JK, et
al: Correction: GATA6 expression distinguishes classical and
basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res.
28:27152022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bártů M, Dundr P, Němejcová K, Tichá I,
Hojný H and Hájková N: The role of HNF1B in tumorigenesis of solid
tumours: A review of current knowledge. Folia Biol (Praha).
64:71–83. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen H, Xu C, Jin Q and Liu Z: S100
protein family in human cancer. Am J Cancer Res. 4:89–115.
2014.PubMed/NCBI
|
|
11
|
Zhou X, Hu K, Bailey P, Springfeld C, Roth
S, Kurilov R, Brors B, Gress T, Buchholz M, An J, et al:
Corrigendum: clinical impact of molecular subtyping of pancreatic
cancer. Front Cell Dev Biol. 11:11795592023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao M, Mishra L and Deng CX: The role of
TGF-β/SMAD4 signaling in cancer. Int J Biol Sci. 14:111–123. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roy N, Takeuchi KK, Ruggeri JM, Bailey P,
Chang D, Li J, Leonhardt L, Puri S, Hoffman MT, Gao S, et al: PDX1
dynamically regulates pancreatic ductal adenocarcinoma initiation
and maintenance. Genes Dev. 30:2669–2683. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim SJ, Choi SJ, Yang J, Kim D, Kim DW,
Byun JH and Hong SM: Pancreatic ductal adenocarcinoma with a
predominant large duct pattern has better recurrence-free survival
than conventional pancreatic ductal adenocarcinoma: A comprehensive
histopathological, immunohistochemical, and mutational study. Hum
Pathol. 127:39–49. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ueno H, Ishiguro M, Nakatani E, Ishikawa
T, Uetake H, Murotani K, Matsui S, Teramukai S, Sugai T, Ajioka Y,
et al: Prognostic value of desmoplastic reaction characterisation
in stage II colon cancer: Prospective validation in a Phase 3 study
(SACURA Trial). Br J Cancer. 124:1088–1097. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fujitani Y: Transcriptional regulation of
pancreas development and β-cell function (Review). Endocr J.
64:477–486. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ding JH, Xiao Y, Zhao S, Xu Y, Xiao YL,
Shao ZM, Jiang YZ and Di GH: Integrated analysis reveals the
molecular features of fibrosis in triple-negative breast cancer.
Mol Ther Oncolytics. 24:624–635. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allison KH, Hammond MEH, Dowsett M,
McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR,
Chavez-MacGregor M, Perlmutter J, et al: Estrogen and progesterone
receptor testing in breast cancer: ASCO/CAP guideline update. J
Clin Oncol. 38:1346–1366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu DD, Guo SW, Jing YY, Dong YL and Wei
LX: A review on hepatocyte nuclear factor-1beta and tumor. Cell
Biosci. 5:582015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao F, Gong W, He H, Zhang Z, Yang H, Shao
F, Gao Y and He J: Integrated multi-omics analysis reveals clinical
significance of hepatocyte nuclear factor-1β in tumor immune
microenvironment, immunotherapy and prognostic prediction for colon
adenocarcinoma. Cancer Immunol Immunother. 74:382024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Hao J, Du Z, Li P, Hu J, Ruan M,
Li S, Ma Y and Lou Q: Inhibition of hepatocyte nuclear factor 1β
contributes to cisplatin nephrotoxicity via regulation of nf-κb
pathway. J Cell Mol Med. 25:2861–2871. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bailey P, Chang DK, Nones K, Johns AL,
Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC,
et al: Genomic analyses identify molecular subtypes of pancreatic
cancer. Nature. 531:47–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kloesch B, Ionasz V, Paliwal S, Hruschka
N, Martinez de Villarreal J, Öllinger R, Mueller S, Dienes HP,
Schindl M, Gruber ES, et al: A GATA6-centred gene regulatory
network involving HNFs and ΔNp63 controls plasticity and immune
escape in pancreatic cancer. Gut. 71:766–777. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martinelli P, Carrillo-de Santa Pau E, Cox
T, Sainz B Jr, Dusetti N, Greenhalf W, Rinaldi L, Costello E,
Ghaneh P, Malats N, et al: GATA6 regulates EMT and tumour
dissemination, and is a marker of response to adjuvant chemotherapy
in pancreatic cancer. Gut. 66:1665–1676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang MX, Coates RF, Ambaye A, Gardner JA,
Zubarick R, Gao Y, Skelly J, Liu JG and Mino-Kenudson M:
Investigation of HNF-1B as a diagnostic biomarker for pancreatic
ductal adenocarcinoma. Biomark Res. 6:252018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Che P, Yang Y, Han X, Hu M, Sellers JC,
Londono-Joshi AI, Cai GQ, Buchsbaum DJ, Christein JD, Tang Q, et
al: S100A4 promotes pancreatic cancer progression through a dual
signaling pathway mediated by Src and focal adhesion kinase. Sci
Rep. 5:84532015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martinelli P, Cañamero M, del Pozo N,
Madriles F, Zapata A and Real FX: Gata6 is required for complete
acinar differentiation and maintenance of the exocrine pancreas in
adult mice. Gut. 62:1481–1488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Andrés MP, Jackson RJ, Felipe I,
Zagorac S, Pilarsky C, Schlitter AM, Martinez de Villareal J, Jang
GH, Costello E, Gallinger S, et al: GATA4 and GATA6
loss-of-expression is associated with extinction of the classical
programme and poor outcome in pancreatic ductal adenocarcinoma.
Gut. 72:535–548. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao Y, Zou X, Wang G, Liu Y, Zhang C, Lu
W and Li Q: Effects of GATA6-AS/MMP9 on malignant progression of
endometrial carcinoma. J BUON. 26:1789–1795. 2021.PubMed/NCBI
|
|
30
|
van Eijck CWF, Real FX, Malats N, Vadgama
D, van den Bosch TPP, Doukas M, van Eijck CHJ and Mustafa DAM;
Dutch Pancreatic Cancer Group (DPCG), : GATA6 identifies an
immune-enriched phenotype linked to favorable outcomes in patients
with pancreatic cancer undergoing upfront surgery. Cell Rep Med.
5:1015572024. View Article : Google Scholar : PubMed/NCBI
|
